Expressão do P16 e do PDGFR-Beta no adenocarcinoma gástrico

Rodrigo Pozza Pinto,Fernando Krebs Cirne Lima,Jane M U Kulkzynski,Luis Fernando Moreira

doi:10.1590/s0100-69912009000300004

Rodrigo Pozza Pinto, Fernando Krebs Cirne Lima + Show 2 more

Open Access

https://doi.org/10.1590/s0100-69912009000300004

Copy DOI

Abstract

To detect immunohistochemistry expression of p16 and PDGFR-beta on gastric adenocarcinoma. Thirty six patients submitted to surgery for gastric adenocarcinoma between 1998 and 2002 at Santa Casa de Porto Alegre Hospital have been studied. Variables investigated were: age, gender, tumour size and localization, number of dissected and metastatic nodes, histological type, surgical resection extension and pathological staging. No expression of PDGFR-beta has been detected on surgical specimens. Concerning to p16, loss of expression lower than 10% and 1% has been detected respectively on 89% and 79% of the specimens studied. There has been no correlation among p16 loss and variables studied.

Highlights

Gastric adenocarcinoma has been the main cause of cancer death during most of the 20th century, overcame by lung cancer
Thirty six patients submitted to surgery for gastric adenocarcinoma between 1998 and 2002 at Santa Casa de Porto Alegre Hospital have been studied with the aim to determine prevalence of p16 and PDGFR-beta
It was a random decision to study simultaneously p16, which loss of expression has been exhaustively studied in gastric tumours and PDGFR-beta, which association to gastric adenocarcinoma has not yet been found in medical literature

Summary

Introduction

Gastric adenocarcinoma has been the main cause of cancer death during most of the 20th century, overcame by lung cancer. Great geographic variations are seen and highest incidences can be found in Japan, South America, Eastern Europe and Middle East[1]. It is twice as frequent in men as in women[1,2], has a low incidence before the 4th decade with a peak incidence in the 7th.[1] In Brazil 23,000 new cases and 11,000 deaths are estimated to occur in 20053. The prognosis of gastric adenocarcinoma is poor, mainly because lack of symptomatology and late diagnosis, with an overall survival of 5-15% in five years[1,4]. Disease recurs in 80% of patients even after curative resection[1]

Methods

Results

Conclusion